NORTHAMPTON, MA / ACCESS Newswire / December 4, 2025 / At MilliporeSigma, the company's ambition is to do business with a ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion. The acquisition – which was confirmed to be in the final stages of ...

New ontologies for process data will help biopharmaceutical manufacturers enhance the interoperability of drug production operations ...

Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company ...

Germany's Merck KGaA is looking at making further acquisitions to boost its business, according to chief executive Belén Garijo. The CEO – who is due to step down next April after five years in the ...

Merck (MRK)’s stock surged by 41% over the past six months, driven not significantly by revenue, but rather by increased profits and heightened investor confidence. Following crucial Q3 earnings ...

This important study shows that different forms and mixtures of cardenolide toxins in tropical milkweed, especially nitrogen- and sulfur-containing types, change how monarch caterpillars eat, grow, ...

Nov 17 (Reuters) - Merck (MRK.N), opens new tab said on Monday it expects a commercial opportunity exceeding $5 billion from Cidara Therapeutics' (CDTX.O), opens new tab experimental flu drug, and ...

Grupo Financiero Valores S.A. FRANKFURT, Nov 20 (Reuters) - Germany's Merck KGaA (MRCG.DE), opens new tab on Thursday agreed to use Boston-based Valo Health's drug research services in a collaboration ...

With a phase 3 win for a combination of its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) and Keytruda, Merck & Co.’s partner Kelun-Biotech is the latest to claim that ...

Merck & Co Inc. is seeking to raise as much as $8 billion through a corporate bond sale, with part of the proceeds expected to help fund its proposed acquisition of Cidara Therapeutics Inc., according ...

Shares of Merck & Company, Inc. (NASDAQ: MRK) are trading higher the FDA approved pembrolizumab with enfortumab vedotin-ejfv for muscle-invasive bladder cancer. MRK shares are powering higher on ...